Beringea is pleased to announce it has invested $2.5 million in Molecular Imaging, a specialty contract research organization (CRO) providing in vivo preclinical imaging services to the pharmaceutical and biotechnology industries to enhance early-stage R&D decision-making.
The capital was part of Molecular Imaging’s over-subscribed $9.9 million Series A financing round, led by Beringea and shared with existing investors Baird Venture Partners, Arcus Ventures and Invest Detroit.
